Sanofi-Aventis inks $690M cancer vaccine deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Sanofi-Aventis |
Oxford BioMedica |
$690M licensing deal |
Sanofi-Aventis has signaled its endorsement of the cancer vaccine field with a $690 million licensing deal for Oxford BioMedica's TroVax. |
|
Eisai |
Morphotek |
$325M buyout |
Japan's Eisai is buying Morphotek in order to add experimental oncology drugs to its pipeline. |
|
AmerisourceBergen |
Bellco Health |
$235M buyout |
Bellco Health is a distributor of branded and generic pharmaceuticals. |
|
Tracon Pharmaceuticals |
Micromet |
$100 million |
Tracon Pharmaceuticals has agreed to pay Micromet more than $100 million in milestones for the successful development of its D93 antibody for cancer. |
|
Bioton |
Biopartners Holdings |
$78M buyout |
Biopartners Holdings makes Valtropin, a human growth hormone that was the second biogeneric therapy to be approved in Europe. |
|
VASTox |
DanioLabs and Dextra Laboratories |
$32M buyout |
The UK's VASTox has simultaneously acquired DanioLabs and Dextra Laboratories. |